JNJ Experienced Huge Adjusted Operational Sales Growth Deceleration With Only +0.8% in the 4Q of 2022, After +8.2% in 3Q of 2022, +8.1% in the 2Q of 2022 and of +7.9% in the 1Q of 2022. Adjusted Operational Sales Growth is the Same as Organic Sales Growth and Excludes the Impacts of Acquisitions, Divestitures, and Foreign Currency Changes. Unfortunately It Also Doesn't Break Out the Two Components of Adjusted Operational Sales Growth ..... Higher Sales Pricing and Sales Volume.

With such very recent huge Sales Growth Deceleration, I now better understand why JNJ is planning a split-up.  

Also JNJ refuses to disclose its Higher Sales Pricing and Sales Volume Components of its Adjusted Operational Sales Growth.  I wonder what % its Tylenol went up in price?

JNJ December 2022 Earnings Release